Golocdacimab Biosimilar Monoclonal Antibody (LOX-1) for Research

Cat No.: GMP-Bios-INN-1220

Anti-OLR1/LOX1 therapeutic antibody (Pre-made Golocdacimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Golocdacimab (development code MEDI-6570) is a monoclonal antibody targeting OLR1 (oxidized LDL receptor 1). It is developed by MedImmune/AstraZeneca. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1220-1mg 1mg 3090
GMP-Bios-INN-1220-10mg 10mg
GMP-Bios-INN-1220-100mg 100mg
GMP-Bios-INN-1220-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Golocdacimab biosimilar, Whole mAb, Anti-OLR1/LOX1 Antibody: Anti-OLR1/LOX1/Oxidized low-density lipoprotein receptor 1/Ox-LDL receptor 1 therapeutic antibody
INN Name Golocdacimab
Target OLR1/LOX1
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Lambda
Highest_Clin_Trial (Jan '20) Phase-II
Est. Status Discontinued
100% SI Structure 7r8u:HL
99% SI Structure None
95-98% SI Structure None
Year Proposed 2022
Year Recommended 2022
Companies MedImmune
Conditions Approved na
Conditions Active na
Conditions Discontinued Atherosclerosis;Coronary disorders
Production na
Development Tech na